Cargando…

Choroidal neovascularization secondary to tuberculosis: Presentation and management()

PURPOSE: While there are many known etiologies of choroidal neovascularization (CNV), tuberculosis is not a well-known causative agent. In this case series, we highlight CNV occurring secondary to tuberculous chorioretinitis, its presentation, and its management. OBSERVATIONS: We retrospectively rev...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee Kim, Esther, Rodger, Damien C., Rao, Narsing A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758031/
https://www.ncbi.nlm.nih.gov/pubmed/29503964
http://dx.doi.org/10.1016/j.ajoc.2016.12.025
_version_ 1783290935440834560
author Lee Kim, Esther
Rodger, Damien C.
Rao, Narsing A.
author_facet Lee Kim, Esther
Rodger, Damien C.
Rao, Narsing A.
author_sort Lee Kim, Esther
collection PubMed
description PURPOSE: While there are many known etiologies of choroidal neovascularization (CNV), tuberculosis is not a well-known causative agent. In this case series, we highlight CNV occurring secondary to tuberculous chorioretinitis, its presentation, and its management. OBSERVATIONS: We retrospectively reviewed the charts and imaging of four patients who presented with presumed tuberculous chorioretinitis and CNV. Three of these patients had signs of intraocular inflammation and were also found to have active macular CNV. The one remaining patient had chorioretinal scars from prior posterior uveitis and previously treated macular CNV membranes. The three patients with active disease were started on anti-tuberculosis medications and oral corticosteroids, and they also received intravitreal anti-vascular endothelial growth factor (VEGF) injections as needed for the CNV. There was a significant improvement in the clinical course of all three patients with active disease—the intraocular inflammation subsided, and CNV recurrences were mitigated. Upon completion of systemic treatment, all patients have remained quiescent. CONCLUSIONS AND IMPORTANCE: Our findings demonstrate that CNV may occur in the course of tuberculous chorioretinitis with marked loss of vision, and management with anti-tuberculosis medications, oral corticosteroids, and intravitreal anti-VEGF injections results in notable improvement in their clinical course.
format Online
Article
Text
id pubmed-5758031
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-57580312018-03-02 Choroidal neovascularization secondary to tuberculosis: Presentation and management() Lee Kim, Esther Rodger, Damien C. Rao, Narsing A. Am J Ophthalmol Case Rep Case report PURPOSE: While there are many known etiologies of choroidal neovascularization (CNV), tuberculosis is not a well-known causative agent. In this case series, we highlight CNV occurring secondary to tuberculous chorioretinitis, its presentation, and its management. OBSERVATIONS: We retrospectively reviewed the charts and imaging of four patients who presented with presumed tuberculous chorioretinitis and CNV. Three of these patients had signs of intraocular inflammation and were also found to have active macular CNV. The one remaining patient had chorioretinal scars from prior posterior uveitis and previously treated macular CNV membranes. The three patients with active disease were started on anti-tuberculosis medications and oral corticosteroids, and they also received intravitreal anti-vascular endothelial growth factor (VEGF) injections as needed for the CNV. There was a significant improvement in the clinical course of all three patients with active disease—the intraocular inflammation subsided, and CNV recurrences were mitigated. Upon completion of systemic treatment, all patients have remained quiescent. CONCLUSIONS AND IMPORTANCE: Our findings demonstrate that CNV may occur in the course of tuberculous chorioretinitis with marked loss of vision, and management with anti-tuberculosis medications, oral corticosteroids, and intravitreal anti-VEGF injections results in notable improvement in their clinical course. Elsevier 2017-01-06 /pmc/articles/PMC5758031/ /pubmed/29503964 http://dx.doi.org/10.1016/j.ajoc.2016.12.025 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case report
Lee Kim, Esther
Rodger, Damien C.
Rao, Narsing A.
Choroidal neovascularization secondary to tuberculosis: Presentation and management()
title Choroidal neovascularization secondary to tuberculosis: Presentation and management()
title_full Choroidal neovascularization secondary to tuberculosis: Presentation and management()
title_fullStr Choroidal neovascularization secondary to tuberculosis: Presentation and management()
title_full_unstemmed Choroidal neovascularization secondary to tuberculosis: Presentation and management()
title_short Choroidal neovascularization secondary to tuberculosis: Presentation and management()
title_sort choroidal neovascularization secondary to tuberculosis: presentation and management()
topic Case report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758031/
https://www.ncbi.nlm.nih.gov/pubmed/29503964
http://dx.doi.org/10.1016/j.ajoc.2016.12.025
work_keys_str_mv AT leekimesther choroidalneovascularizationsecondarytotuberculosispresentationandmanagement
AT rodgerdamienc choroidalneovascularizationsecondarytotuberculosispresentationandmanagement
AT raonarsinga choroidalneovascularizationsecondarytotuberculosispresentationandmanagement